Agilent beats quarterly results on strong demand from biotech clients
Aug 21 (Reuters) -Agilent Technologies A.N on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies.
"While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated", said CEO Padraig McDonnell.
The public funding environment for early-stage biotechs is expected to improve in the second half of this year, on hopes of interest rate cuts by the Federal Reserves in September. Some analysts have noted that funding for biotechs could stabilize due to a strong 2023 for U.S. regulatory approvals.
Last month, Agilent's larger peer Thermo Fisher TMO.N also raised its annual profit outlook as the company banks on improved demand for its tools and services used in biopharma.
California-based Agilent on Wednesday raised the lower end of its forecasts for both full-year revenue and profit.
It now expects full-year revenue of $6.45 billion to $6.5 billion, compared with estimates of $6.46 billion, according to LSEG data. It had previously forecast a range of $6.42 billion to $6.5 billion.
The company expects to earn between $5.21 to $5.25 per share for fiscal 2024, compared with its previous forecast of between $5.15 to $5.25 per share.
Agilent reported a third-quarter adjusted profit of $1.32 per share for the quarter ended July 31, beating analysts' estimates of $1.26 per share.
It reported quarterly revenue of $1.58 billion, above estimates of $1.56 billion.
Reporting by Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi and Shailesh Kuber
免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。